EMD Millipore Contract Research Laboratory for Drug Discovery and Development Services Receives CLIA Certification

EMD Millipore's Discovery and Development Solutions business, part of the Life Science division of Merck KGaA of Darmstadt, Germany, today announced Clinical Laboratory Improvement Amendments (CLIA) certification of its contract research lab located in St Louis.

EMD Millipore Discovery and Development Solutions is a leading provider of outsourced bioanalytical services, focused on biotherapeutics. The company has 25 years experience developing and performing immunoassays on human and animal specimens and offers biomarker analysis on a variety of therapeutic applications including: diabetes, infection, neurodegenerative disease, osteoporosis, and cancer.

"Obtaining CLIA certification is an important milestone for EMD Millipore," said Christina Shasserre, Vice President of Discovery and Development Services. "We have been operating under Good Lab Practice (GLP) Standards for many years to deliver high quality data to our customers. The addition of CLIA requirements enables us to bring those standards to the next level and help our customers make their pipeline decisions in confidence. This certification is another example of our continuing commitment to address customers' evolving needs."

Through CLIA, the Centers for Medicare & Medicaid Services (CMS) regulate all laboratory testing performed on humans in the United States. CLIA regulation ensures the accuracy, reliability and timeliness of tests, regardless of where the tests are performed. Mandated by the Code of Federal Regulations, the CMS has primary responsibility for the operation of the CLIA program.